EP Patent

EP3280703A1 — Deuterium-substituted oxadiazoles

Assigned to Auspex Pharmaceuticals Inc · Expires 2018-02-14 · 8y expired

What this patent protects

Described are deuterated modulators of S1P1 receptors, pharmaceutical compositions thereof, and methods of use thereof.

USPTO Abstract

Described are deuterated modulators of S1P1 receptors, pharmaceutical compositions thereof, and methods of use thereof.

Drugs covered by this patent

ozanimod-hydrochloride (OZANIMOD HYDROCHLORIDE)

Patent Metadata

Patent number: EP3280703A1
Jurisdiction: EP
Classification: —
Expires: 2018-02-14
Drug substance claim: No
Drug product claim: No
Assignee: Auspex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.